Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Cash & Equivalents (2017 - 2025)

Historic Cash & Equivalents for Cue Biopharma (CUE) over the last 9 years, with Q3 2025 value amounting to $11.7 million.

  • Cue Biopharma's Cash & Equivalents fell 6390.81% to $11.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.7 million, marking a year-over-year decrease of 6390.81%. This contributed to the annual value of $22.5 million for FY2024, which is 5370.61% down from last year.
  • As of Q3 2025, Cue Biopharma's Cash & Equivalents stood at $11.7 million, which was down 6390.81% from $27.5 million recorded in Q2 2025.
  • In the past 5 years, Cue Biopharma's Cash & Equivalents ranged from a high of $73.9 million in Q2 2021 and a low of $11.7 million during Q3 2025
  • In the last 5 years, Cue Biopharma's Cash & Equivalents had a median value of $51.6 million in 2022 and averaged $46.6 million.
  • As far as peak fluctuations go, Cue Biopharma's Cash & Equivalents soared by 21263.66% in 2021, and later crashed by 6798.36% in 2025.
  • Over the past 5 years, Cue Biopharma's Cash & Equivalents (Quarter) stood at $64.4 million in 2021, then dropped by 19.82% to $51.6 million in 2022, then dropped by 6.01% to $48.5 million in 2023, then plummeted by 53.71% to $22.5 million in 2024, then tumbled by 47.9% to $11.7 million in 2025.
  • Its last three reported values are $11.7 million in Q3 2025, $27.5 million for Q2 2025, and $13.1 million during Q1 2025.